TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00938522
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the cilostazol group received 200 mg of cilostazol (loading dose) 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
Study: NCT03044184
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transamine is an antifibrinolytic medication given systemically via the intravenous route
Study: NCT03639142
Drug: Polyethylene Glycol 4000
Normalized name: Polyethylene glycol 4000
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive PEG at dose 0,5 g/kg/d once daily orally, for 4 weeks.
Study: NCT02499042
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oxygen delivery by ETT/ SGA connected to bag/valve/oxygen reservoir
Study: NCT03668405
Drug: Lu AF20513
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT03437707
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
Study: NCT04523935
Drug: Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs were used either singly or in combination guided by clinical findings and investigations.
Study: NCT03096912
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ribociclib Oral 600 mg x 1 a day 21 days on 1 week off in 28 days cycles
Study: NCT02955823
Drug: Rituximab-Dexamethasone-Lenalidomide
Normalized name: Lenalidomide
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1. st CYCLE: Rituximab 375 mg/m2 i.v. on days 1,8,15; Dexamethasone 5 mg p.o. on days 1,8,15,22; Lenalidomide 15 mg/day p.o. day 2-22~2. nd-4th CYCLE: Rituximab 375 mg/m2 i.v. on day 1; Lenalidomide 20 mg/day p.o. from day 2 to day 22 At the end of 4th CYCLE disease restaging: - if ≥ PR continues with the 5th and 6th cycle: Rituximab 375 mg/m2 i.v. on day 1, Lenalidomide 20 mg /day p.o. day 2-22~   * if \<PR stops the treatment, only follow-up At the end of the 6th CYCLE disease restaging: - if ≥ PR continues with beyond the 6th cycle with Lenalidomide 10mg dd1-21q28 until cycle 12th~  * if \<PR stops the treatment, only follow-up Then, accordingly response rate after the sixth cycle assessment(≥ PR) lenalidomide will be continued at 10 mg dd1-21q28 until 12th cycle or unacceptable toxicity.
Study: NCT01166412
Drug: levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6.5mg patch daily for 11 weeks
Study: NCT01166412
Drug: levonorgestrel patch with BMI <32 kg/m2
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6.5mg patch daily for 11 weeks
Study: NCT01166412
Drug: levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12.5mg patch daily for 11 weeks
Study: NCT01166412
Drug: levonorgestrel patch with BMI <32 kg/m2
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12.5mg patch daily for 11 weeks
Study: NCT01449019
Drug: exendin(9-39)amide
Normalized name: EXENDIN (9-39)
DrugBank: Avexitide (DB14806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of exendin(9-39)
Study: NCT01449019
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion of saline
Study: NCT03669029
Drug: Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clinical response at week 6,14, 30 and 54 will be correlated to serum golimumab levels and anti-golimumab antibody levels.
Study: NCT03669029
Drug: Golimumab treatment optimization.
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab dosing will be optimized in patients without clinical response at week 6.
Study: NCT01206335
Drug: OHR/AVR118
DrugBank: AVR118 (DB04979)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHR/AVR118 given subcutaneously at 4mL per day
Study: NCT02357836
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, Post-treatment assessments will include a skin biopsy, blood draw for the PK (pharmacokinetics) analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure.
Study: NCT00649012
Drug: Pioglitazone HCl Tablets 45 mg
Normalized name: Pioglitazone Hydrochloride
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45mg, single dose fed
Study: NCT00752375
Drug: Trimethoprim Sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Children \>3months of age will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)per day for one year.~* Children under 3 months of age will receive amoxicillin 10mg/kg once per day for one year.~* Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day for one year.
Study: NCT04475601
Drug: Enzalutamide Pill
Normalized name: enzalutamide Pill
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The once daily dose will be given only during hospitalization and stop if starting invasive mechanical ventilation or at discharge from hospital
Study: NCT01142219
Drug: L-arginine
Normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.
Study: NCT00149851
Drug: Tegaserod
Normalized name: Tegaserod
DrugBank: Tegaserod (DB01079)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02134314
Drug: C1 Esterase Inhibitor
Normalized name: C1 esterase inhibitor
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1 Esterase Inhibitor 50 units per kilogram intravenous infusion administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
Study: NCT00344682
Drug: memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: memantine 5mg - 20mg PO daily
Study: NCT00257192
Drug: Ziprasidone oral capsules
Normalized name: ziprasidone Oral Capsule
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg BID to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
Study: NCT04641364
Drug: human albumin injection
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple doses of intravenous infusion
Study: NCT01926041
Drug: Varenicline for tobacco smoking cessation
Normalized name: TOBACCO SMOKE
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The 16-week varenicline course conforms to real-practice government regulations in Taiwan.
Study: NCT01879618
Drug: Fragmin
Normalized name: Fragmin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: variable dosing regimen
Study: NCT04026438
Drug: Potassium Phosphate Injection
Normalized name: dibasic potassium phosphate / potassium phosphate Injection
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One ml of the preparation contains 3 mmol of phosphorous which when equated with RDA 10ml ie 30 mmol of preparation will be supplemented. The preparation is given slowly, intravenously over 4 hours diluted in 500 ml normal saline
Study: NCT02890199
Drug: Bupivacaine liposomal
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02890199
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01052987
Drug: Tranilast
Normalized name: Tranilast
DrugBank: Tranilast (DB07615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranilast tablets, 300 mg, QD
Study: NCT03329261
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: COPIGREL® - clopidogrel dosed at 75 mg per tablet
Study: NCT03429543
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: At least 1000 mg/day or up to a maximal tolerated dose.
Study: NCT03429543
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal or multiple dose injection.
Study: NCT01052987
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol tablets 300 mg, QD
Study: NCT01052987
Drug: Combination - Tranilast and Allopurinol
Normalized name: allopurinol, combinations
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranilast, 300 mg QD; Allopurinol 300 mg QD
Study: NCT01052987
Drug: 400 mg Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg Allopurinol administered once daily for 7 days
Study: NCT01052987
Drug: High dose combination
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Tranilast 300 mg once daily for 7 days plus Allopurinol 400 mg once daily for 7 days
Study: NCT01035255
Drug: Enalapril 10 mg BID
Normalized name: enalapril 10 MG
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril 10 mg BID
Study: NCT02427594
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug/dietary supplement is used in a crossover design to lower the nonvolatile acid load of the diet compared to the control period.
Study: NCT01786616
Drug: Formoterol
Normalized name: Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03429543
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 film-coated tablet Linagliptin once daily, until end of treatment.
Study: NCT03429543
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 film-coated tablet of Empagliflozin once daily, until end of treatment.
Study: NCT03472378
Drug: DFN-15
Normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [DFNDR SUNSCREEN SPF 50]
DrugBank: Avobenzone (DB09495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Solution of 4.8 mL containing 120 mg of DFN-15
Study: NCT02940483
Drug: 5-Azacytidine
Normalized name: 5-azacytidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5-Azacytidine 10 mg into the fourth ventricle of the brain via the Ommaya reservoir 1 day a week for 12 weeks.
Study: NCT03575520
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A fixed dose of 6.0 mg pegteograstim was administered subcutaneously on day 2 of each chemotherapy cycle (between 22 and 26 hours after the completion of chemotherapy).
Study: NCT04285346
Drug: Ganaxolone
Normalized name: ganaxolone
DrugBank: Ganaxolone (DB05087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: titration followed by maintenance and extension period
Study: NCT01599468
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/kg of tranexamic acid as induction dose within 12 minutes and 1mg/Kg/h as maintenance within the 2 following hours
Study: NCT03823417
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous TXA given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
Study: NCT01096082
Drug: Lithium Carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg tablets, starting dose 300 mg/day
Study: NCT00003943
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5
Study: NCT00003943
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 250 mg/m2
Study: NCT00003943
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2
Study: NCT00003019
Drug: vinblastine sulfate
Normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03431675
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose oral ciprofloxacin
Study: NCT00047281
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00047281
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01596075
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol will be dissolved in oil to a predefined concentration.Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade\>2). Cannabidiol will be given up to 90 days.
Study: NCT03949049
Drug: Citicoline
Normalized name: Citicoline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citacoline as neuroprotector
Study: NCT03229759
Drug: Octenidine Dihydrocloride in aqueous solution
Normalized name: octenidine
DrugBank: Octenidine (DB12624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: application of investigational product
Study: NCT00505700
Drug: velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00505700
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00505700
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00527111
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00527111
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01727726
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tablet/capsule
Study: NCT01727726
Drug: Seroquel XR
Normalized name: Seroquel XR
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet/capsule
Study: NCT02352051
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
Study: NCT02352051
Drug: methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg
Study: NCT03013491
Drug: CX-072
Normalized name: Cx-072 probody
DrugBank: Pacmilimab (DB18873)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03013491
Drug: ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03013491
Drug: vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00262262
Drug: Levetiracetam (drug)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The starting dose of levetiracetam was 500 mg/day and the dose was increased with 500 mg every other day to 6 tablets of 500 mg (Keppra, UCB, Belgium), divided into two doses daily corresponding to 3000 mg/day. The dose was kept at this level throughout the remaining treatment period - 4 weeks total. Six placebo tablets with identical appearance were dosed similarly to levetiracetam in the placebo phase.
Study: NCT00757562
Drug: desloratadine
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: desloratadine syrup: 1.25 mg (2.5 mL) for subjects \>=2 to \<6 years, 2.5 mg (5 mL) for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.
Study: NCT00148460
Drug: TNK-tPA
Normalized name: TNK-tPA
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00148460
Drug: rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01675804
Drug: Ritalin
Normalized name: Ritalin
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -drug therapy: 2 or 3 doses of 10 mg tablets of Immediate-release Methylphenidate (Ritalin) per day for 2 months.
Study: NCT04072146
Drug: OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross over bioavailability study
Study: NCT00705224
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Ribavirin was taken orally as 200 mg gelatinous capsules. The daily dose varied from 800 to 1200 mg (depending on patient's body weight) twice daily in the~morning and in the evening with meal. Therapy duration varied from 24 to 48 weeks depending on HCV genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply.
Study: NCT03901612
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous post operative regional analgesia
Study: NCT00668434
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.
Study: NCT02458079
Drug: Pentoxiphylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04238663
Drug: MB02 (Bevacizumab Biosimilar)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
Study: NCT00429377
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04611711
Drug: decitabine＋ TQB2450 injection
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.
Study: NCT04611711
Drug: decitabine＋ TQB2450 injection＋Anlotinib
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.~Anlotinib Hydrochloride is a multi-target receptor tyrosine kinase inhibitor with significant inhibitory activity against angiogenesis related kinases (VEGFR1/2/3, FGFR1/2/3, etc.) and other tumor cell proliferation-related kinases (PDGFR /, C-Kit, RET, etc.), which can play a dual role in anti-tumor angiogenesis and tumor growth inhibition.
Study: NCT03184909
Drug: Ocimum Sanctum
Normalized name: Ocimum Sanctum
DrugBank: Ocimum tenuiflorum top (DB14273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active capsules containing leaves of organically prepared ocimum sanctum
Study: NCT00406575
Drug: Recombinant human relaxin (rhRlx)
Normalized name: Human relaxin recombinant
DrugBank: Serelaxin (DB05794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.